The sentiment of investors fell to 1.52 in Q2 2019. Its 0.07 down from 1.59 in Q1 2019. It is falling, with 10 investors selling DRNA stocks while 21 holdings are being lowered. 19 Fund positions were opened while 28 stakes were raised. 45,15 million shares or 2,31% less than 46,22 million shares in Q1 2019. The Florida Retirement System State Board of Administration revealed a stake of 21,334 shares. For 24,495 shares, Millennium owns 0.04 percent of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA). Los Angeles Cap Equity Rech recorded 11,980. Adage Cap Prtn Grp Ltd Co holds a share of 0.11% or 2.80M. Alliancebernstein Limited Partnership has invested in 0% or 65,600 shares. Ameritas Inv Prtn’s 4,450 shares were recorded. Nuveen Asset Mngmt Ltd Liability Company invested 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA). Moreover, Fmr Limited Liability has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA). In Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), Swiss-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0 percent. The California-based fund, Charles Schwab Invest Mngmt, recorded 302,337 stocks. State Of Wisconsin Invest Board reported 75,600 shares. Morgan Stanley has 0% invested in Dicerna Pharmaceuticals, Inc.
It has had 0 insider purchases since May 29, 2019, and 1 sale for $20.00 million.
Based on its recent statutory filing with the SEC in 2019Q2, the University Of Notre Dame Du Lac improved its stake in Dicerna Pharmaceuticals Inc (DRNA) by 215.18 percent. University of Notre Dame Du Lac purchased 518,836 shares as the inventory of the company increased by 8.52 percent. At the end of 2019Q2, the institutional investor held 759,949 healthcare company shares, valued at $11.97 million, up from 241,113 at the end of the year.
University Of Notre Dame Du Lac, which manages a portfolio of approximately $440.79 M US Long, decreased its stake in Heron Therapeutics Inc (NASDAQ: HRTX) by 210,012 shares to 202,693 shares, valued at $3.77 M in 2019Q2, as reported.